Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is one of the best yield companies with high dividend expectations.
  • The tendency within the weekly time frame is positive above the technical support level at 77.6 CHF
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Technically, the stock approaches a strong medium-term resistance at CHF 85.15.
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • With an enterprise value anticipated at 4.37 times the sales for the current fiscal year, the company turns out to be overvalued.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
NOVARTIS13.09%221 731
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386
AMGEN21.32%128 515
SANOFI-4.07%109 152
BAYER6.02%103 473
BRISTOL-MYERS SQUIBB COMPAN..8.61%102 146
NOVO NORDISK A/S29.37%102 077
ABBOTT LABORATORIES42.49%96 603
ELI LILLY AND COMPANY19.50%95 289
CELGENE CORPORATION-6.52%86 140
GLAXOSMITHKLINE-17.09%84 827
ASTRAZENECA9.99%82 988
ALLERGAN PLC-19.41%57 098
More Results
Financials ($)
Sales 2017 49 174 M
EBIT 2017 11 962 M
Net income 2017 7 505 M
Debt 2017 17 812 M
Yield 2017 3,36%
P/E ratio 2017 24,57
P/E ratio 2018 21,41
EV / Sales 2017 4,87x
EV / Sales 2018 4,66x
Capitalization 222 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart NOVARTIS
Duration : Period : Day
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Duration : Period : Week
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders